Exicure Drug May Revolutionize Stem Cell Transplants with Rapid Action

REDWOOD CITY, CA – February 05, 2026 – A new publication is highlighting a potential paradigm shift in cancer treatment, detailing a drug that dramatically accelerates a critical component of stem cell transplantation. Exicure, Inc. announced that results from a Phase 2 study of its drug, burixafor, were published in the peer-reviewed journal Annals of Hematology, showcasing the drug’s ability to mobilize stem cells at a speed that far outpaces current standards of care.

The findings suggest that burixafor could significantly reduce the time, cost, and patient burden associated with autologous stem cell transplantation (ASCT), a cornerstone therapy for blood cancers like multiple myeloma and lymphoma. By enabling stem cell collection on the same day it is administered, the drug promises to transform the complex logistics of a procedure that hundreds of thousands of patients have undergone worldwide.

A New Pace for a Lifesaving Procedure

For decades, ASCT has offered a lifeline to patients with aggressive hematologic cancers. The procedure involves harvesting a patient’s own hematopoietic stem cells, administering high-dose chemotherapy to eradicate the cancer, and then reinfusing the collected cells to rebuild the patient's blood and immune systems. A crucial and often challenging step is the initial harvest, or mobilization, where stem cells are coaxed out of the bone marrow and into the bloodstream for collection via a process called leukapheresis.

Standard practice involves treatment with granulocyte colony-stimulating factor (G-CSF), often supplemented with a CXCR4 inhibitor for patients who mobilize poorly. The current market-leading inhibitor, plerixafor (Mozobil), has been a valuable tool, but it requires a waiting period of 10 to 14 hours between injection and peak cell mobilization. This necessitates overnight hospital stays or carefully timed next-day appointments, adding logistical complexity and stress for patients.

Burixafor, also a CXCR4 inhibitor, appears to shatter this timeline. The study published in Annals of Hematology details how burixafor achieved peak mobilization of CD34+ stem cells within just one hour of administration. In the 12-participant trial involving patients with multiple myeloma, non-Hodgkin’s lymphoma, and Hodgkin disease, 11 of 12 individuals (92%) successfully collected the target number of stem cells within two apheresis sessions. Remarkably, half of the participants met the goal in a single session.

“Efficient mobilization of peripheral blood progenitor cells is critical to achieving reliable engraftment while minimizing patient burden and overall healthcare costs,” said Michael Schuster, MD, Clinical Professor of Medicine at Stony Brook University and a study author. “In this study, burixafor demonstrated enhanced mobilization kinetics that led to significantly faster attainment of stem cell collection goals, highlighting its differentiated profile and potential to meaningfully improve the efficiency of cell collection for ASCT.”

Clinical Evidence and a Competitive Edge

The promising data is not limited to a single study. Exicure recently completed an additional Phase 2 trial that combined burixafor with G-CSF and propranolol, a beta-blocker, based on preclinical data suggesting the combination could further enhance mobilization. Topline results, presented at major medical conferences in late 2025 and early 2026, reinforced the drug's rapid action and efficacy. In that study of 20 multiple myeloma patients, 90% achieved the collection goal, including 85% of patients who had received prior therapies known to make mobilization more difficult.

Across both studies, burixafor has been generally well tolerated, with a favorable safety profile reporting only low-grade adverse events. While the trials have involved small patient numbers, as is typical for this stage of development, the consistency of the results has built a strong case for the drug's unique properties. The ability to reliably and rapidly mobilize stem cells, even in challenging patient populations, gives burixafor a distinct competitive advantage over the existing standard of care.

The implications for hospitals and patients are profound. Same-day administration and collection could reduce the need for hospital beds, optimize the use of expensive apheresis equipment, and allow for more flexible patient scheduling. For patients, this could mean fewer hospital visits, less time away from home and family, and a less arduous start to the difficult transplant journey.

Beyond Transplant: A Gateway to Future Therapies

While the immediate impact of burixafor is focused on improving existing cancer therapies, its mechanism may unlock a far broader range of applications. The study noted that in addition to stem cells, burixafor prompted a marked increase in circulating lymphocytes, with counts increasing up to 11-fold within hours in some patients.

This capability is particularly relevant to the burgeoning field of cell and gene therapy. Advanced treatments like CAR-T therapy, where a patient's own immune cells are engineered to fight cancer, depend on the efficient collection of healthy lymphocytes. Likewise, gene-editing therapies for inherited conditions like sickle cell disease require harvesting a robust supply of hematopoietic stem cells for modification outside the body.

As Dr. Schuster noted, the “rapid and predictable mobilization of CD34-positive cells and lymphocytes may also be highly relevant for emerging gene-based and gene-editing approaches.” By providing a tool that can quickly and reliably supply the necessary cellular raw material, burixafor could become an essential enabling technology, accelerating the development and accessibility of these cutting-edge treatments.

A Strategic Bet for Exicure

For Exicure, burixafor represents a major strategic pivot and a potential company-defining asset. The drug entered its pipeline following the acquisition of GPCR Therapeutics in January 2025, shifting the company’s focus squarely toward hematologic diseases. The consistent stream of positive data since the acquisition has validated the strategic move, positioning Exicure as a serious contender in the hematology and cell therapy support space.

However, the path from promising clinical data to market approval is fraught with financial and regulatory challenges. Like many clinical-stage biotechs, Exicure faces the ongoing need to secure substantial funding to advance burixafor through larger, more expensive Phase 3 trials and potential commercialization. The company's success will depend not only on the drug's ultimate performance but also on its ability to navigate the complex financial landscape of drug development.

With a clear clinical advantage in hand, Exicure is already looking to expand burixafor’s potential. The company is planning a chemosensitization trial in acute myeloid leukemia (AML), based on the hypothesis that mobilizing cancerous cells out of the protective bone marrow niche could make them more vulnerable to chemotherapy. This strategy, if successful, would open yet another significant therapeutic front for its lead candidate.